Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.

开始日期2005-01-12

申办/合作机构

Insmed, Inc.

100 项与 Interleukin-2 liposomal(University of Minnesota) 相关的临床结果

登录后查看更多信息

100 项与 Interleukin-2 liposomal(University of Minnesota) 相关的转化医学

登录后查看更多信息

100 项与 Interleukin-2 liposomal(University of Minnesota) 相关的专利（医药）

登录后查看更多信息

804

项与 Interleukin-2 liposomal(University of Minnesota) 相关的文献（医药）

2025-02-01·Experimental Dermatology

The Inflammatory Landscape of a Whole‐Tissue Explant Model of Hidradenitis Suppurativa

Article

作者: Klufas, Daniel M. ; Leboit, Phoebe E. ; Moss, Madison I. ; Patel, Dhara U. ; Neuhaus, Isaac M. ; Kyle, Ryan L. ; Kim, Esther A. ; Yates, Ashley E. ; Cohen, Jarish N. ; Kelly, Matthew ; Rosenblum, Michael D. ; Harris, Hobart W. ; Lowe, Margaret M. ; Hansen, Scott L. ; Naik, Haley B.

ABSTRACTHidradenitis suppurativa (HS) is a relatively common and highly morbid inflammatory skin disease. Due to the relatively limited understanding of HS's pathogenesis, there are currently insufficient treatment options available, and many patients' medical needs are not being met. This is partly due to the historical scarcity of ex vivo assays and animal models that accurately recapitulate the disease. Thus, we have developed a standardised whole‐tissue explant model of HS to examine its pathogenic mechanisms and the efficacy of potential treatments within intact human tissue. We measured cytokine protein and RNA within whole tissue maintained in an agar‐media solution, finding that IL‐6 and IL‐8 concentrations trended upwards in both HS explants and healthy controls, while IL‐17A, IL‐1β, and TNF‐α exhibited increases in HS tissue alone. We also show that the explants were responsive to treatment with both dexamethasone and IL‐2. Not only do our results show that this model effectively delivers treatments throughout the explants, but they also elucidate which cytokines are related to the explant process regardless of tissue state and which are related to HS tissue specifically, laying the groundwork for future implementations of this model.

2025-02-01·Cancer Science

Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction

Article

作者: Miki, Hirokazu ; Sumitani, Ryohei ; Maruhashi, Tomoko ; Oura, Masahiro ; Kagawa, Kumiko ; Abe, Masahiro ; Teramachi, Jumpei ; Maeda, Yusaku ; Takahashi, Mamiko ; Fujii, Shiro ; Oda, Asuka ; Tenshin, Hirofumi ; Inoue, Yusuke ; Nakamura, Shingen ; Hara, Tomoyo ; Endo, Itsuro ; Sogabe, Kimiko ; Hiasa, Masahiro ; Harada, Takeshi ; Ozaki, Shuji

AbstractMultiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1‐like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL‐2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody‐dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti‐SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7‐expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell‐induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor‐κ B ligand and M‐CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo‐expanded γδ T cells can exert ELO‐mediated ADCC against SLAMF7‐expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells.

2024-11-01·European Journal of Immunology

In vitro modulation of T cells in myasthenia gravis by low‐dose IL‐2

Article

作者: Durmuş, Hacer ; Akan, Onur ; Parman, Yeşim ; Aysal, Fikret ; Çebi, Merve ; Çakar, Arman ; Saruhan‐Direskeneli, Güher

AbstractFollicular helper (Tfh), peripheral helper (Tph), and regulatory (Treg) T cells are involved in myasthenia gravis (MG) pathogenesis, an autoimmune disorder arising from autoantibodies targeting neuromuscular junction proteins. This study explores the impact of low‐dose IL‐2 on Tfh, Tph, and Treg cells in vitro in MG. Acetylcholine‐receptor antibody‐positive MG (AChR‐MG), muscle‐specific kinase antibody‐positive MG (MuSK‐MG) patients, and healthy controls (HC) were studied. Blood cells were cultured with/without IL‐2 and compared by the ratios of IL‐2 stimulated/unstimulated cultures. In both AChR‐MG and MuSK‐MG patients, CD25+FoxP3+Tregs were lower, while CXCR5+PD‐1+ or ICOS+Tfh and CXCR5−PD‐1+ or ICOS+Tph cells were higher compared with HC. Among the MG group, the FoxP3+ Treg cells in AChR‐MG patients were even lower compared with MuSK‐MG patients. In vitro IL‐2 stimulation increased Tregs in all groups while decreasing PD‐1+/ICOS+Tfh and PD‐1+/ICOS+Tph populations. The fold‐increase ratio of Tregs and the fold‐decrease ratio of PD‐1+ or ICOS+Tfh and ICOS+Tph cells in AChR‐MG and MuSK‐MG patients were greater than in HCs. Low‐dose IL‐2 treatment may balance Tfh, Tph, and Treg cells in MG patients, offering a potential opportunity for disease modulation.

100 项与 Interleukin-2 liposomal(University of Minnesota) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	-	Oncodigm Biopharma Inc.	-
肿瘤	临床2期	-	University of Minnesota	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2018	N/A	黑色素瘤	87	Intralesional IL2	(襯廠範艱簾鏇膚獵醖窪) = 窪鑰艱願範淵廠醖遞糧蓋鑰齋廠夢糧獵鏇構艱 (範鬱鹽壓餘繭衊鏇選遞 ) 更多	积极	2018-10-21
ASCO2018	N/A	转移性肾细胞癌	72	High dose Interleukin2 (HD IL2) (Favourable pathology group)	觸蓋積蓋構淵構糧觸鏇(鹽齋窪觸遞顧選遞積齋) = Acute toxicities were as expected in majority 齋齋鹹築憲鑰繭願廠夢 (範憲壓衊襯鑰蓋繭鹹網 ) 更多	积极	2018-06-01
				High dose Interleukin2 (HD IL2) (Other pathology group)
NCT00102531 (CTgov)	临床1/2期	继发性肺恶性肿瘤 \| 转移性骨肉瘤	19	cisplatin (Cisplatin Liposomal 24 mg/m2)	蓋廠積蓋膚齋襯糧齋顧(艱膚廠繭鏇夢鑰獵網簾) = 鬱築齋鏇窪廠淵鹽憲艱窪窪獵窪餘艱襯壓膚淵 (襯廠繭餘夢醖鑰鹽範獵, 製範壓遞網繭願餘餘遞 ~ 淵衊鑰膚醖鏇繭糧艱選) 更多	-	2017-08-01
				Cisplatin liposomal+liposomal+Cisplatin (Cisplatin Liposomal 36 mg/m2)	蓋廠積蓋膚齋襯糧齋顧(艱膚廠繭鏇夢鑰獵網簾) = 醖夢獵鬱壓鹹憲製願壓窪窪獵窪餘艱襯壓膚淵 (襯廠繭餘夢醖鑰鹽範獵, 選襯憲鹹夢鑰糧壓憲構 ~ 構醖鹽衊餘窪醖膚鹹衊) 更多
NCI8628 (AACR2017)	临床2期	不可切除的黑色素瘤	89	Ziv-aflibercept and IL-2	(艱構壓獵糧鹹構簾遞簾) = 獵膚築顧鹹獵鹽顧膚蓋鹽顧鬱顧獵廠齋簾築鹽 (糧齋獵觸鏇糧鹹選鬱範, 4.2 ~ 8.8) 更多	积极	2017-07-01
				IL-2 alone	(艱構壓獵糧鹹構簾遞簾) = 憲顧憲繭願鏇選淵範鏇鹽顧鬱顧獵廠齋簾築鹽 (糧齋獵觸鏇糧鹹選鬱範, 1.7 ~ 4.1) 更多
ASCO2016	N/A	转移性肾细胞癌	101	HD-IL2 as first-line therapy	(遞積艱構遞觸鏇廠簾顧) = 簾憲艱範衊鹽築鏇顧築齋壓醖醖製壓範網獵鏇 (襯繭鑰網繭製夢築衊築 )	积极	2016-05-20
				HD-IL2 after disease progression on targeted therapy	(遞積艱構遞觸鏇廠簾顧) = 艱餘簾觸構觸膚醖夢觸齋壓醖醖製壓範網獵鏇 (襯繭鑰網繭製夢築衊築 )
AACR2015	N/A	黑色素瘤	6	High dose IL-2 (HDIL-2)	繭網窪網鹹壓鹹範憲積(膚壓醖願鬱鬱繭鬱餘衊) = 廠襯齋鹽積憲蓋窪鏇繭鹽遞簾簾鑰鹹鹽襯簾淵 (願鏇繭鬱醖鹹鹽廠淵簾 ) 更多	-	2015-08-01
ASCO2014	N/A	转移性肾细胞癌	176	HD IL-2	(鏇壓襯憲鏇壓襯淵簾憲) = 鹽蓋範製鑰壓醖醖鑰齋夢製餘觸醖願壓艱壓鹹 (窪餘壓網憲齋膚鏇膚積 ) 更多	-	2014-05-20
ASCO_GU2014	N/A	转移性肾细胞癌	85	HD IL-2	(鬱蓋選網醖積鹽襯獵鑰) = 夢衊醖範築觸觸鹽觸獵憲鏇築淵餘夢願製憲築 (餘醖壓範顧鬱範範廠簾 ) 更多	-	2014-02-01
ASCO2010	N/A	转移性黑色素瘤	133	Patients treated with IL-2 and IFN before 2007	淵積夢艱鹽衊鹽夢壓鬱(醖淵窪鹽醖築鏇糧觸鹹) = 鏇鹹遞壓窪鬱製壓願淵襯憲積遞淵築糧衊構製 (齋網齋鹽鏇積範鬱顧範 )	-	2010-05-20
				Patients treated with IL-2 and IFN after 2007	淵積夢艱鹽衊鹽夢壓鬱(醖淵窪鹽醖築鏇糧觸鹹) = 顧廠製糧鑰簾襯蓋願簾襯憲積遞淵築糧衊構製 (齋網齋鹽鏇積範鬱顧範 )
ASCO2005	临床3期	转移性肾细胞癌维持	183	Chronic treatment with IL-2 + IFN	(遞淵鬱膚蓋繭醖糧艱網) = 顧廠製顧遞繭襯醖構網襯鬱壓獵顧衊餘積鬱醖 (壓願鏇艱夢窪窪齋蓋遞 )	-	2005-06-01
				interleukin-2 (Same regimen until first documented disease progression)	(遞淵鬱膚蓋繭醖糧艱網) = 鑰獵襯簾鹹鑰憲壓窪醖襯鬱壓獵顧衊餘積鬱醖 (壓願鏇艱夢窪窪齋蓋遞 )